CWM
LGND icon

Cabot Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Cabot Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-81,375
Closed -$5.18M – 151
2016
Q3 		$5.18M Buy
+81,375
New +$5.97M 1.33% 24

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cabot Wealth Management's LGND Position: Q4 2016 in Review

Cabot Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2016, closing a stake of 81,375 shares — an estimated $5.18M sold.

Cabot Wealth Management first reported a position in LGND in Q3 2016 and held it in 1 quarter. The position peaked at $5.18M in Q3 2016. 269 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

  • Cabot Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Cabot Wealth Management sold 81,375 Ligand Pharmaceuticals shares in Q4 2016, an estimated $5.18M.
  • Cabot Wealth Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Cabot Wealth Management's Ligand Pharmaceuticals position peaked at $5.18M in Q3 2016.
  • 269 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on Cabot Wealth Management's 13F filing for Q4 2016, filed 7 Feb 2017.